IL143296A0 - Use of human prostate cell lines in cancer treatment - Google Patents

Use of human prostate cell lines in cancer treatment

Info

Publication number
IL143296A0
IL143296A0 IL14329699A IL14329699A IL143296A0 IL 143296 A0 IL143296 A0 IL 143296A0 IL 14329699 A IL14329699 A IL 14329699A IL 14329699 A IL14329699 A IL 14329699A IL 143296 A0 IL143296 A0 IL 143296A0
Authority
IL
Israel
Prior art keywords
cell lines
cancer treatment
human prostate
prostate cell
derivatives
Prior art date
Application number
IL14329699A
Other languages
English (en)
Original Assignee
Onyvax Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyvax Ltd filed Critical Onyvax Ltd
Publication of IL143296A0 publication Critical patent/IL143296A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
IL14329699A 1998-12-10 1999-12-09 Use of human prostate cell lines in cancer treatment IL143296A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9827104.2A GB9827104D0 (en) 1998-12-10 1998-12-10 New cancer treatments
PCT/GB1999/004129 WO2000033869A2 (en) 1998-12-10 1999-12-09 Use of human prostrate cell lines in cancer treatment

Publications (1)

Publication Number Publication Date
IL143296A0 true IL143296A0 (en) 2002-04-21

Family

ID=10843926

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14329699A IL143296A0 (en) 1998-12-10 1999-12-09 Use of human prostate cell lines in cancer treatment
IL143296A IL143296A (en) 1998-12-10 2001-05-22 Factor containing a line of prostate cells, preparations containing it and use in the treatment of prostate cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL143296A IL143296A (en) 1998-12-10 2001-05-22 Factor containing a line of prostate cells, preparations containing it and use in the treatment of prostate cancer

Country Status (19)

Country Link
US (3) US6972128B1 (OSRAM)
EP (1) EP1137422B1 (OSRAM)
JP (2) JP4949554B2 (OSRAM)
KR (1) KR20010090874A (OSRAM)
AT (1) ATE304365T1 (OSRAM)
AU (1) AU763485B2 (OSRAM)
CA (1) CA2354045C (OSRAM)
CZ (1) CZ300499B6 (OSRAM)
DE (1) DE69927286T2 (OSRAM)
ES (1) ES2249046T3 (OSRAM)
GB (1) GB9827104D0 (OSRAM)
HU (1) HUP0104568A3 (OSRAM)
IL (2) IL143296A0 (OSRAM)
MX (1) MXPA01005816A (OSRAM)
NO (1) NO327044B1 (OSRAM)
NZ (1) NZ512004A (OSRAM)
PL (1) PL201016B1 (OSRAM)
WO (1) WO2000033869A2 (OSRAM)
ZA (1) ZA200104164B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
GB9827103D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
WO2000071156A2 (en) * 1999-05-21 2000-11-30 Onyvax Limited New vaccine formulations-3
US7303911B2 (en) 2000-04-01 2007-12-04 Onyvax Limited Prostate cell lines
US6667479B2 (en) * 2001-06-01 2003-12-23 Raytheon Company Advanced high speed, multi-level uncooled bolometer and method for fabricating same
US20050019336A1 (en) * 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment
BRPI0414014A (pt) * 2003-08-26 2006-10-24 Becton Dickinson Co métodos para distribuição intradérmica de agentes terapêuticos
CN101646455A (zh) 2007-02-07 2010-02-10 财团法人阪大微生物病研究会 用于癌症的治疗剂
EP2216041A4 (en) * 2007-11-20 2012-10-24 Nec Corp METHOD OF INDUCING A CYTOTOXIC T-CELL, CYTOTOXIC T-CELL INDUCTOR AND PHARMACEUTICAL COMPOSITION, AND VACCINE WITH THE INDUCTOR
AU2009200767A1 (en) * 2008-03-10 2009-09-24 Aristocrat Technologies Australia Pty Limited A gaming system and a method of gaming
EP2376089B1 (en) 2008-11-17 2018-03-14 The Regents of the University of Michigan Cancer vaccine compositions and methods of using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3580371B2 (ja) * 1991-10-04 2004-10-20 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ サイトカインおよび抗原を用いた全身の免疫応答の調節
JPH05246889A (ja) * 1992-03-05 1993-09-24 Seitai Chiyousetsu Kenkyusho:Kk 制癌方法および制癌剤
WO1995029704A1 (en) * 1994-04-28 1995-11-09 Scott Freeman Cell lines obtained by in vivo migration and by fusion with autoimmune cells
BR9607894A (pt) * 1995-03-17 1999-06-01 Univ California Processo para tratar tumores
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
DE69627527T2 (de) * 1995-12-28 2004-03-04 The Johns Hopkins University School Of Medicine Allogene parakrine cytokine tumor impfstoffe
JP2000506379A (ja) * 1996-02-02 2000-05-30 アメリカ合衆国 ヒト前立腺上皮不死細胞の細胞株およびクローンおよびそれらの研究および前立腺癌治療に対する応用
GB9620350D0 (en) * 1996-09-30 1996-11-13 Maudsley David J Cancer vaccine
US6207805B1 (en) * 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments

Also Published As

Publication number Publication date
US6972128B1 (en) 2005-12-06
AU763485B2 (en) 2003-07-24
JP2012021028A (ja) 2012-02-02
NZ512004A (en) 2003-08-29
AU1668300A (en) 2000-06-26
US20050249756A1 (en) 2005-11-10
DE69927286D1 (de) 2005-10-20
ATE304365T1 (de) 2005-09-15
CZ20012032A3 (cs) 2001-10-17
JP2002531520A (ja) 2002-09-24
CA2354045C (en) 2012-02-21
ES2249046T3 (es) 2006-03-16
PL201016B1 (pl) 2009-02-27
DE69927286T2 (de) 2006-06-29
EP1137422A2 (en) 2001-10-04
EP1137422B1 (en) 2005-09-14
US8034360B2 (en) 2011-10-11
ZA200104164B (en) 2002-01-24
CZ300499B6 (cs) 2009-06-03
PL348828A1 (en) 2002-06-17
JP4949554B2 (ja) 2012-06-13
CA2354045A1 (en) 2000-06-15
MXPA01005816A (es) 2002-03-27
KR20010090874A (ko) 2001-10-19
WO2000033869A2 (en) 2000-06-15
NO327044B1 (no) 2009-04-06
HUP0104568A3 (en) 2004-05-28
NO20012634L (no) 2001-08-08
IL143296A (en) 2006-06-11
GB9827104D0 (en) 1999-02-03
NO20012634D0 (no) 2001-05-29
US20120164099A1 (en) 2012-06-28
WO2000033869A3 (en) 2000-10-12
HUP0104568A2 (hu) 2002-03-28

Similar Documents

Publication Publication Date Title
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
MXPA03001645A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
MXPA03011985A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
NO20021830L (no) Sammensetninger egnet til å forhindre og behandle forkjölelse og influensaliknende symptomer samt fremgangsmåter vedfremstilling derav
AU2592600A (en) Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
IL143296A0 (en) Use of human prostate cell lines in cancer treatment
MXPA01010982A (es) Uso de phyllanthus para la estimulacion dirigida al objetivo del sistema inmune.
PT967987E (pt) Composicoes para o tratamento de tumores contendo extractos de cartilagem de tubarao e agentes antineoplasicos
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
IL136960A0 (en) Combination therapy for the treatment of migraine
EP1335719A4 (en) TREATMENT OF ECZEMAS AND / OR PSORIASIS
EP1578760A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS
IS2254B (is) Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
IL131478A0 (en) Methods for treatment of scar tissue
IL139144A0 (en) Mycobacterial inhibitors
ZA200003235B (en) Combination therapy for the treatment of migraine.
IL136025A0 (en) Combination therapy for the treatment of migraine
MXPA03001644A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
TR199802496T2 (xx) Konjestif kalp yetmezli�ini tedavi i�in form�lasyon.
IL136024A0 (en) Combination therapy for the treatment of migraine
PL1827403T3 (pl) Kompozycje do leczenia stanów patologicznych powierzchni oka
IL148336A (en) Medicaments that contain xenogeneic oligo and/or polyribonucleotides
AU5434899A (en) Cancer treatment

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed